Royalty and Commercial Payment Purchase Agreements - Viracta (Details) $ in Thousands |
6 Months Ended | |||
|---|---|---|---|---|
|
Mar. 22, 2021
USD ($)
item
|
Jun. 30, 2023
USD ($)
|
Jun. 30, 2022
USD ($)
|
Dec. 31, 2022
USD ($)
|
|
| Agreements | ||||
| Payments of consideration under RPAs, AAAs and CPPAs | $ 14,650 | $ 5,000 | ||
| Long-term royalty and commercial payment receivables | 72,232 | $ 63,683 | ||
| Viracta | Royalty Purchase Agreement | ||||
| Agreements | ||||
| Number of drug candidates | item | 2 | |||
| Payments of consideration under RPAs, AAAs and CPPAs | $ 13,500 | |||
| Maximum amount of potential milestones and other payments receivable | 54,000 | |||
| Amount of maximum consideration retained | 20,000 | |||
| Maximum amount of potential regulatory and commercial milestones receivable | 57,000 | |||
| Long-term royalty and commercial payment receivables | $ 13,500 | |||
| Amount of allowance for credit losses | $ 0 | $ 0 | ||
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of allowance for credit loss for right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of drug candidates under the terms of the agreement. No definition available.
|
| X | ||||||||||
- Definition Long-term royalty and commercial rights receivables, non current. No definition available.
|
| X | ||||||||||
- Definition Amount of maximum consideration retained by Company excluded from maximum potential milestones under terms of agreement. No definition available.
|
| X | ||||||||||
- Definition Maximum amount of potential milestones and other payments receivable, excluding consideration retained by company under the terms of the agreement. Excludes regulatory and commercial milestones. No definition available.
|
| X | ||||||||||
- Definition Amount of cash outflow for consideration under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), and Commercial payment purchase agreement. (CPPAs) classified as investing activities. Payments may include upfront payments, one-time payments, milestone payments and contingent consideration payments. No definition available.
|
| X | ||||||||||
- Definition Maximum amount of potential regulatory and commercial milestones receivable under the terms of the agreement. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|